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Adrenal cortex tumors are divided into benign forms, such as primary hyperplasias and 
adrenocortical adenomas (ACAs), and malignant forms or adrenocortical carcinomas 
(ACCs). Primary hyperplasias are rare causes of adrenocorticotropin hormone-indepen-
dent hypercortisolism. ACAs are the most common type of adrenal gland tumors and 
they are rarely “functional,” i.e., producing steroids. When functional, adenomas result 
in endocrine disorders, such as Cushing’s syndrome (hypercortisolism) or Conn’s syn-
drome (hyperaldosteronism). By contrast, ACCs are extremely rare but highly aggressive 
tumors that may also lead to hypersecreting syndromes. Genetic analyses of patients 
with sporadic or familial forms of adrenocortical tumors (ACTs) led to the identification 
of potentially causative genes, most of them being involved in protein kinase A (PKA), 
Wnt/β-catenin, and P53 signaling pathways. Development of mouse models is a crucial 
step to firmly establish the functional significance of candidate genes, to dissect mech-
anisms leading to tumors and endocrine disorders, and in fine to provide in vivo tools 
for therapeutic screens. In this article, we will provide an overview on the existing mouse 
models (xenografted and genetically engineered) of ACTs by focusing on the role of PKA 
and Wnt/β-catenin pathways in this context. We will discuss the advantages and limita-
tions of models that have been developed heretofore and we will point out necessary 
improvements in the development of next generation mouse models of adrenal diseases.
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iNTRODUCTiON
Adrenocortical tumors (ACTs) are classified as benign adrenocortical adenomas (ACAs) and malig-
nant adrenocortical carcinomas (ACCs). Most ACTs are benign, unilateral, and non-secreting ade-
nomas, often discovered incidentally during abdominal imaging for reasons unrelated with adrenal 
gland (adrenal “incidentalomas”). Although less frequently, ACAs may be secreting tumors associated 
Abbreviations: ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma; ACT, adrenocortical tumor; ACTH, adreno-
corticotropin hormone; APA, aldosterone-producing adenoma; CPA, cortisol-producing adenoma; CS, Cushing’s syndrome; 
GIP, gastric inhibitor polypeptide; GPCR, G-protein-coupled receptors; LH/hCG, luteinizing hormone/choriogonaotropin; 
PA, primary aldosteronism; PBMAH, primary bilateral macronodular adrenal hyperplasia; PKA, protein kinase A; PPNAD, 
primary pigmented nodular adrenal hyperplasia; SF-1, steroidogenic factor 1.
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with endocrine hyperfunction that leads to several symptoms and 
significant morbidity. Indeed, clinical manifestations of secreting 
ACAs differ depending on their secretion profile. Cortisol-
producing adenomas (CPAs) lead to Cushing’s syndrome (CS). 
Notably, hypercortisolism associated with unilateral ACAs is the 
most common form of adrenocorticotropin hormone (ACTH)-
independent CS (1, 2). Aldosterone-producing adenomas (APAs) 
lead to primary aldosteronism (PA). APAs, together with bilateral 
hyperplasia, comprise 95% of all PA cases (3).
Although bilateral forms of ACTs are less frequent, several 
adrenal pathological conditions converge in the group of diseases 
termed adrenocortical hyperplasia, characterized by bilateral 
adrenal enlargement. Primary bilateral macronodular adrenal 
hyperplasia (PBMAH) is the most common and is a rare cause 
of CS. The report of familial forms and the bilateral nature sug-
gest a genetic origin for PBMAH (4). Unlike PBMAH, primary 
pigmented nodular adrenal hyperplasia (PPNAD) is rarer but it 
may cause overt Cushing (5).
Contrary to ACAs, ACCs are extremely rare, with an 
annual incidence of 0.5–2 cases per million. However, they are 
highly aggressive tumors associated with poor prognosis and 
often diagnosed at an advanced stage (6, 7). They can occur 
at any age but the incidence in children is particularly high 
in southern Brazil due to the high prevalence of a specific 
TP53 mutation (8). Besides tumor growth and metastasis, 
clinical manifestations of ACCs are often the result of steroid 
hypersecretion caused by endocrine dysfunction, reminiscent 
of adrenal adenomas.
Over the last 5  years, genetic analyses of patients with spo-
radic or familial forms of ACTs has resulted in identification of 
alterations in a new set of genes, most of them being involved 
in cAMP/protein kinase A (PKA) and Wnt/β-catenin signal-
ing pathways (9–11) (Figures  1 and 2). The major difference 
in the prevalence of ACA and ACC in patients suggests that 
adenomas are not precursors of malignant neoplasms. Moreover, 
the malignant transformation of a benign and non-functional 
adrenal tumor is very rare (12–14). Notably, the risk that an 
adrenal incidentaloma progresses to a malignant tumor has 
recently been estimated as almost zero by the European Society 
of Endocrinology (ESE). Consequently, European recommenda-
tions for the clinical management of patients with non-functional 
ACAs have been reconsidered and modified to avoid unnecessary 
procedures (European Congress of Endocrinology, May 2016, 
Munich, Germany  –  Symposium 5: ESE clinical guidelines: 
Management of adrenal incidentaloma: http://www.ece2016.org/
scientific-programme/). By contrast, secreting ACAs are surgi-
cally removed, which prevents evaluation of a possible benign 
to malignant continuum in functional adenomas. In fact, the 
hypothesis that ACC could develop in a multistep process from 
normal adrenal to adenoma followed by malignant transforma-
tion relied on one case report in which a carcinoma emerged in 
the center of a surrounding benign ACT (15). However, some 
genome-wide approaches performed on independent cohorts to 
analyze genomic changes and gene regulation in ACTs suggests 
that cancers could result from pangenomic cumulative changes 
occurring in a multistep tumor progression (16–18). Although 
it is important to predict to what extent a benign lesion can be 
considered as the precursor of malignancy, analysis of patients’ 
data may not be sufficient to provide a definitive conclusion.
The use of small animals for modeling tumors in a controlled 
experimental manner is a valuable strategy to explore the func-
tional significance of mutations, to dissect mechanisms underlying 
both adrenocortical tumorigenesis and endocrine disorders, and 
to provide in vivo tools to screen for novel therapeutic approaches. 
To date, several genetically modified and xenografted mouse mod-
els have been developed to investigate the involvement of specific 
pathways and the heterogeneous nature of ACTs, respectively. 
Although models established until now have shed light on impor-
tant aspects of adrenocortical diseases, many of them failed to fully 
mimic tumors found in human adrenals (Table 1). Hence, there is 
a strong need to develop relevant mouse models to shed light on 
mechanisms involved in the initiation and progression of adrenal 
tumors. In this article, we provide an overview of the existing mouse 
models (xenografted and genetically engineered) of ACTs relevant 
to human ACTs, including adrenal hyperplasia. We will discuss 
limitations of models that have been developed heretofore and 
we will point out necessary improvements in the development of 
next-generation mouse models of adrenal diseases. Notably, these 
models should allow, on the one hand, to firmly establish the role 
of newly identified genes in adrenocortical tumorigenesis and, on 
the other hand, to explore the interplay between pathways shown 
to be associated with ACTs (e.g., cAMP/PKA and Wnt/β-catenin).
BeNiGN ADReNOCORTiCAL TUMORS 
AND ASSOCiATeD HYPeRSeCReTiON 
SYNDROMeS
Primary Bilateral Macronodular  
Adrenal Hyperplasia
Primary bilateral macronodular adrenal hyperplasia is a rare 
cause of CS, accounting for <2% of all endogenous CS cases 
(33, 34). PBMAH is characterized by the presence of adreno-
cortical nodules larger than 10 mm and it is often diagnosed in 
patients between 40 and 60  years of age, with clinical signs of 
cortisol excess and suppressed levels of plasma ACTH. PBMAH 
was first described by Kirschner and colleagues (35) and it was 
named ACTH-independent macronodular adrenal hyperplasia 
(AIMAH). However, it has been recently found that cortisol 
production in PBMAH is not truly ACTH independent, since a 
population of adrenocortical cells in the hyperplastic tissue can 
produce ACTH that in turn stimulates cortisol secretion through 
autocrine and paracrine mechanisms (36). Hence, the term 
“ACTH independent” is not entirely appropriate for this disorder. 
Although in the majority of cases, PBMAH appears to be spo-
radic, several cases of familial clustering have been reported in the 
last years (37–39). However, the true prevalence of the familial vs. 
sporadic form is unknown, as systematic familial screening has 
not been conducted.
Aberrant Hormone Receptors in PBMAH  
and Related Mouse Models
The mechanism by which cortisol production is stimulated in 
PBMAH, despite suppressed plasma ACTH, was previously 
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FiGURe 1 | PKA signaling pathway in adrenal tumorigenesis and related mouse models. (A) Under normal conditions, ACTH binds to MC2R, a  
G-protein-coupled receptor (GPCR) that activates adenylate cyclase (AC) via Gsα, thus increasing intracellular levels of cAMP. Upon binding of cAMP to regulatory 
subunits (R) of PKA, the complex dissociates releasing the catalytic subunits (C) which in turn phosphorylate (among others) the cAMP-responsive element-binding 
protein (CREB). Once phosphorylated, CREB transcription factor regulates the expression of steroidogenic and proliferative genes. In absence of ACTH, the 
pathway is repressed through the activity of several phosphodiesterases (PDE) that inactivate cAMP. (B) Molecular alterations of several components of cAMP/PKA 
signaling pathway cause adrenal hyperplasias and tumors. (1) Activating mutations of MC2R found in PBMAH patients lead to higher activation of the pathway. No 
mouse model is actually available for Mcr2 activating mutations. (2) Hormones other than ACTH (GIP/hCG/LH), through ectopic expression of several GPCRs, may 
induce ACTH-independent hypercortisolism in PBMAH patients. Xenograft mouse models nicely recapitulate this pathologic context. (3) Activating mutations in 
GNAS gene, encoding for the subunit α of the stimulatory G protein, causes higher activation of the pathway. These mutations are the cause of adrenal hyperplasia 
associated with Cushing’s syndrome in Mc-Cune Albright syndrome, whereas somatic mutations have been found in cortisol-producing adenomas. No mouse 
model is actually available for Gnas-activating mutations. (4) Inactivating mutations in PDE genes lead to an accumulation of cAMP, thus causing the persistent 
activation of the pathway in absence of ACTH and they have been associated with PBMAH and hypercortisolism. Whole-body PDE8B knockout mice developed 
mild hyperplasia. (5a) Most inactivating mutations in the PRKARIA gene, encoding the 1α regulatory subunit (R1α) of the PKA, lead to aberrant transcripts and to 
the absence of the protein, resulting in constitutive activation of PKA. Adrenocortical-specific Prkar1a knockout (AdKO) mice develop a PPNAD-like syndrome with 
adrenal hyperplasia and ACTH-independent hypercorticosteronism. (5b) Some PRKARIA gene mutations lead to expressed mutated (truncated) R1α proteins that 
also cause increased PKA activation. These mutations are associated with a more severe phenotype for reasons still not understood to date. No mouse model is 
available for expressed mutated R1α proteins. (6) Mutations in the PRKACA gene encoding for the catalytic subunit α (Cα) of the PKA alter its interaction with 
regulatory subunits leading to constitutive activation of PKA-Cα and increased steroidogenesis. These mutations have been identified in many patients with 
cortisol-producing adenomas. No mouse model is actually available for Prkaca activating mutations. (7) Inactivating germline and somatic mutations in the 
armadillo repeat-containing 5 (ARMC5) gene have been identified in ~50% of patients with PBMAH. The function and the mechanisms by which ARMC5 
contributes to the pathogenesis of PBMAH are unknown. In vitro studies suggest a role in steroidogenesis and apoptosis processes and a possible interplay with 
the PKA pathway, which is supported by the association of ARMC5 mutations with particular expression profile of GPCRs. No loss of function mouse model is 
actually available for Armc5.
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unknown and was referred to as being “autonomous.” Several 
groups have then shed light on the pathogenesis of hypercor-
tisolism in PBMAH. They reported that in most patients with 
PBMAH and in some adenomas, cortisol secretion is regulated 
by hormones other than ACTH, through the aberrant expression 
of several G-protein-coupled receptors (GPCRs) that are nor-
mally absent (ectopic) or expressed at lower levels in the adrenal 
cortex (40–42). The GPCRs for gastric inhibitory polypeptide 
(GIP), catecholamines, vasopressin, serotonin, and luteinizing 
hormone/human chorionic gonadotropin (LH/hCG) have been 
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FiGURe 2 | wNT/β-catenin signaling pathway in adrenal tumorigenesis. (A) In the absence of Wnt ligands, b-catenin is phosphorylated by a complex 
composed of GSK3b, CK1, APC, and AXIN. This phosphorylation targets b-catenin to proteosomal degradation, thus preventing its nuclear translocation. In this 
context, the T cell-specific factors (Tcf)/lymphoid enhancer-binding factor (Lef) represses target genes expression through association with transcriptional inhibitors. 
Secreted frizzled related proteins (SFRP) can inhibit extracellular Wnt signaling. (B) When WNT signaling is active, binding of Wnt ligands to their receptor complex 
(Frizzled/LRP5/6) induces the recruitment of Disheveled (Dsv) to the cytoplasmic domain of Frizzled and the phosphorylation of the cytoplasmic tail of LRP5/6 by 
CK1 and GSK3b. This induces delocalization of Axin to LRP5/6 and sequestration of the degradation complex. b-catenin degradation is, thus, reduced and it 
accumulates. Accumulated b-catenin enters the nucleus, binds to LEF/TCF transcription factors, and activates transcription of target genes. Mutations in several 
members of WNT/β-catenin signaling pathway have been identified in adrenal hyperplasias, adenomas, and carcinomas. Several mouse models have been 
developed to induce constitutive β-catenin activation either through adrenal cortex specific loss of Apc (1) or the expression of a protein resistant to phosphorylation 
and ubiquitin-dependent degradation (2). Loss of ZNRF3, a potential Wnt signaling inhibitor, has been identified as the major genetic alteration in adrenal carcinoma. 
Mouse model with adrenal specific inactivation of Znrf3 is required to assess its causal involvement in ACC.
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shown to be involved in adrenal CS development (42). GIP-
dependent CS has been reported in patients with PBMAH and 
with unilateral adenomas (33, 43, 44). In these patients, plasma 
cortisol levels were increased following meals, despite ACTH 
suppression, and paralleled postprandial elevation of GIP plasma 
concentrations. Hypercortisolism associated with aberrant LH/
hCG receptors was first identified in a woman with transient CS 
during sequential pregnancies and persistent CS after menopause 
(45). Since then, several cases of PBMAH with aberrant LHR 
have been reported, alone or in association with GIPR (45, 46). 
The molecular mechanisms responsible for aberrant expression 
of these receptors are unknown as no genetic mutations have 
been found in the coding or regulatory regions of receptor genes. 
Furthermore, whether expression of these receptors is a primary 
or a secondary event in the pathogenesis of PBMAH is still a 
matter of debate. Several lines of evidence support the hypothesis 
that it is a causative factor. First, aberrant receptors are almost 
universally present in PBMAH and at early stages (47). Second, 
the same aberrant receptors were found in all members of some 
affected families (37, 48), although this was not found in a known 
Brazilian family (39). Further data supporting a triggering role 
of ectopic receptors in PBMAH came from xenotransplantation 
mouse models. Indeed, to investigate the role of ectopic GIPR 
and LHR expression in the development of PBMAH, Mazzuco 
and colleagues used an in vivo model of cell transplantation and 
tissue reconstruction. Primary bovine adrenocortical cells were 
genetically engineered to express GIPR or LHR (retrovirus-
mediated enforced expression) and transplanted under the 
kidney capsule of adrenalectomized immunodeficient mice (49, 
50). Transplantation of GIPR- or LHR-expressing cells induced 
the formation of hyperplasic and hypertrophic adrenocortical 
tissues. The growth advantage provided by aberrant receptors 
expression at least relied on increased proliferation rates of trans-
plants but the downstream mechanisms supporting proliferation 
were not explored. These models nicely recapitulated the context 
of human PBMAH with GPCR-dependent CS. Indeed, LHR-
dependent CS is not exclusively observed during pregnancies or 
after menopause (41). Likewise, in the LHR xenotransplanted 
TABLe 1 | Current mouse models of adrenocortical tumors and their limitations.
Model Gene Promoter/driver Adrenocortical phenotype Limitation Reference
Men1± Men1 Whole-body KO Hyperplasia, adenoma, carcinoma (lack of tumor grade 
definition)
Multiple tumors (19, 20)
Prkar1a2Δ/+ Prkar1a EIIA-Cre No adrenal phenotype No adrenal phenotype (21)
tTA/X2AS Prkar1a Tet-Off system Hyperplasia maintaining of X-zone Technical limitations, 
reproducibility
(22)
AdKO Prkar1a 0.5 Akr1b7-Cre Expansion of X-like zone with zona fasciculata features, 
autonomous corticosterone secretion
Late phenotype (23)
Pde8b−/− Pde8b Whole-body KO Mild hyperplasia No adrenal-specific ablation (24)
ΔCat Ctnnb1 0.5 Akr1b7-Cre Hyperplasia, adenoma and ectopic zona glomerulosa, 
hyperaldosteronism
Rare carcinomas (25)
APC-KO Apc Sf1-Crelow Hyperplasia progressed to microscopic and 
macroscopic adenomas
Progression to carcinoma 
was never observed
(26)
APC KO-H19ΔDMD Apc Igf2/H19 ICR Sf1-Crelow Hyperplasia and adenomas, more severe phenotype 
than APC-KO mice
One carcinoma (26)
PEPCK-IGF Igf2 Pepck-Igf2 Hyperplasia No adrenocortical tumors (27)
ΔCat; AdIgf2 Ctnnb1 Igf2 0.5 Akr1b7-Cre Hyperplasia, adenoma, slight increased proliferation 
compared to ΔCat mice
Moderate effect on tumor 
progression
(28)
0.5 Akr1b7-Igf2
4.5 Scc-Igf2
Acdacd/acd; p53± Acd, Tp53 Increased development of ACC compared to Acdacd/acd Multiple tumors (29)
Inhα/TAg SV40 (large T antigen) 6kb inhibinα-TAg Malignant ACTs developing upon gonadectomy Unrelated to human 
pathology
(30)
AdTAg SV40 (large T antigen) 0.5 Akr1b7-TAg Rapidly evolving tumors (31)
YAC TR NR5A1 YAC transgene Hyperplasia and tumors Tumors with gonadal 
phenotype
(32)
MEN1, multiple endocrine neoplasia type 1; Prkar1a, Protein kinase cAMP-dependent regulatory subunit type I alpha; Akr1b7, aldo-keto reductase family 1, member b7; 
Pde8b, phosphodiesterase 8b; Ctnnb1, catenin (cadherin-associated protein), beta 1; APC, adenomatous polyposis coli; KO, knockout; ICR, imprinting control region; PEPCK, 
phosphoenolpyruvate carboxykinase; IGF2, insulin-like growth factor 2; Acd, adrenocortical dysplasia; TP53, tumor protein P53; TAg, tumor antigen; SV40, simian virus 40; YAC, 
yeast artificial chromosome; Nr5a1, nuclear receptor subfamily; tTA/X2AS, transgenic mouse carrying an antisense transgene for Prkar1a exon 2 (X2AS) under the control of a 
tetracycline responsive promoter; ΔCat, Catnblox(ex3) line x 0.5AkR1b7-Cre.
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model, the hyperplastic tissue formed in the absence of supra-
physiological levels of plasma LH. This shows a direct role of 
aberrant LHR expression in the pathogenesis of PBMAH with 
LH-responsive CS, even though the molecular mechanisms 
leading to ectopic expression of GPCRs in adrenocortical cells 
are still unknown.
Xenotransplantation models developed by Mazzuco et al. are 
not easy to manage for long-term follow-up or for assessment 
of therapeutic strategies, because immunodeficient mice with 
CS have short life expectancy. However, this elegant approach 
combining genetic engineering and cell transplantation of bovine 
adrenal cells in mice may be a useful tool to test the cooperation 
of multiple genetic alterations in the tumorigenic process (51) 
or when genetic alterations may be not relevant in mouse (e.g., 
KCNJ5 gene, see Aldosterone-Producing Adenomas: WNT 
Pathway, KCNJ5, and Lack of Mouse Models).
Familial Forms of PBMAH, Genetic  
Alterations, and Related Mouse Models
Reports of rare familial forms and the bilateral nature of these 
tumors support a genetic origin of PBMAH. Many genes are 
associated with the development of PBMAH, including genes 
causing hereditary familial tumor syndromes, such as APC 
(52,  53), MEN1 (54), and FH (55). Moreover, several reports 
pointed out genes involved in the cAMP/PKA signaling pathway, 
such as PDE8B and PDE11A (56, 57), MC2R (58), GNAS (59), and 
PRKACA (9) (Figure 1). Mutations in members of cAMP/PKA 
pathway are predicted to over-activate the pathway but they have 
been observed in a limited number of patients (Figure 1).
Germline inactivating mutations of the MEN1 gene cause a 
complex genetic syndrome named multiple endocrine neoplasia 
type 1 (MEN1) characterized by endocrine and non-endocrine 
tumors (60). PBMAH occurs in ~21% of MEN1 patients (54). 
Two whole-body Men1 KO mouse models have been reported. 
They nicely recapitulate the spectrum of tumors of MEN1 syn-
drome, including adrenocortical lesions. Specifically, whereas 
homozygous whole-body Men1 KO is embryonic lethal (19, 20), 
heterozygous mice are viable and develop tumors similar to those 
found in the human disease, including adrenocortical hyperpla-
sia that seems to progress from adenoma to carcinoma (20). Of 
note, characterization of the histological phenotype, allowing 
establishment of tumor grade, was not detailed in this paper. 
Therefore, the conclusion that a multi-step tumor progression 
process occurs in Men1 adrenal tumors should be taken with 
caution (Table 1). Since MEN1 has recently been identified as a 
significantly mutated gene in ACC (11), Men1 KO mice could be 
useful to identify novel actors and mechanisms underlying the 
evolution of benign ACTs to malignancy.
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Although the bilateral nature and the multifocal nodules 
suggest an important role of genetic factors in PBMAH, genetic 
defects summarized above account for only a few cases of this 
adrenal disease. More recently, inactivating germline and somatic 
mutations in the armadillo repeat-containing 5 (ARMC5) gene 
have been identified in ~50% of patients with apparently sporadic 
PBMAH and also in a large family with genetically transmitted 
PBMAH (10, 39, 61, 62). ARMC5 is a tumor suppressor gene with 
the typical “two-hit” pattern of mutations: a first germline muta-
tion and a second somatic one. The function and the mechanisms 
by which ARMC5 contributes to the pathogenesis of PBMAH are 
unknown. However, in vitro studies suggest a role in steroidogen-
esis and apoptosis processes (10). Indeed, ARMC5 inactivation in 
cultured adrenocortical cells decreases the expression of MC2R 
and of various steroidogenic enzymes, both in basal conditions 
and after cAMP stimulation (10), suggesting that it may interfere 
with PKA pathway by impairing the stimulation of its target genes 
(Figure 1). Increased cell survival upon ARMC5 inactivation is 
proposed to trigger hyperplasia while subclinical CS could be the 
result of the major increase in adrenal mass that would compen-
sate for decreased per-cell steroidogenic activity. Furthermore, 
ARMC5 mutations seem to be associated with particular 
expression profile of GPCRs, i.e., beta-adrenergic and dopamine 
receptors (10). This observation supports the hypothesis of a link 
between ARMC5 and PKA signaling, as the abnormal expression 
of GPCRs leads to activation of PKA signaling, normally trig-
gered by the ACTH receptor (MC2R) (Figure 1). Further in vitro 
studies and the development of knockout models are required 
to shed light on the ARMC5-dependent network that triggers 
development of PBMAH and CS. Notably, the combination of 
adrenal targeted GPCRs overexpression and Armc5 knockout 
could provide information on a possible cooperation between 
ARMC5 and PKA signaling.
Primary Pigmented Nodular 
Adrenocortical Disease and  
Related Mouse Models
Primary pigmented nodular adrenocortical disease is a type of 
adrenal hyperplasia characterized by the presence of cortisol-
secreting bilateral adrenal micronodules (<1  cm). PPNAD is 
the most common endocrine manifestation of Carney complex 
disease (CNC), an autosomal-dominant multiple neoplasia syn-
drome (63). More than 60% of CNC patients harbor mutations 
in the PRKARIA gene, encoding the regulatory subunit 1α (R1α) 
of PKA (64) (Figure  1). Specifically, inactivating heterozygous 
germline mutations are observed in about two-thirds of Carney 
Complex patients and loss of heterozygosity (LOH) has been 
reported, indicating that PRKARIA acts as a tumor suppressor 
gene (64). Interestingly, somatic inactivating mutations have 
also been found in ACTs (65). Several mouse models have 
been developed to target Prkar1a gene inactivation by different 
strategies (Table 1). Total Prkar1a KO mice had severe defects in 
mesoderm development and died at E9.5 (66). Mice heterozygous 
for a null allele of Prkar1a developed several tumors but had no 
adrenal phenotype (21). An antisense RNA approach was devel-
oped to achieve a more severe loss of R1α than in heterozygous 
KO mice (22). This allowed a 70% decrease in Prkar1a, causing 
several neoplastic manifestations, including mild adrenocortical 
hyperplasia. Interestingly, adrenocortical manifestations in the 
antisense RNA model included maintenance of the X-zone, a 
normally transient zone of fetal origin. To achieve bi-allelic inac-
tivation without compromising mouse survival, we generated an 
adrenocortical-specific Prkar1a knockout mouse model (AdKO) 
(23) by crossing Prkar1a-floxed strain with Akr1b7-Cre mice, 
thereby targeting specific genetic ablation in adrenocortical cells 
from E14.5 (67) (Figures 1 and 3; Table 1). These mice developed 
a PPNAD-like syndrome with ACTH-independent hyper-corti-
costeronism and adrenal hyperplasia, composed of hypertrophic 
cells emerging from the innermost cortex. Endocrine overactivity 
was associated with unbuffered PKA catalytic activity, which 
resulted in overexpression of steroidogenic genes. Interestingly, 
fetal-like hyperplasia centrifugally expanded with aging at the 
expense of the normal adult cortex, which underwent progres-
sive atrophy. This mouse model confirmed the important role of 
PKA pathway in adrenal hyperplasia and shed light on possible 
mechanisms responsible for PPNAD. The most likely mechanism 
to explain the defective zonal differentiation and cell renewal in 
AdKO mice is an impaired capacity of adult progenitor cells of the 
outer cortex to undergo centripetal differentiation and increased 
survival of cells in the inner cortex that would then cumulate 
both fetal-like and fasciculata cell features. We further showed 
that PKA-dependent induction of mTOR signaling was one of 
the mechanisms participating in the resistance to apoptosis, lead-
ing to both hyperplasia and cell hypertrophy, typical of PPNAD 
(68,  69). Altogether, these observations suggest that PPNAD 
should be considered as a developmental disease.
To further elucidate the molecular mechanisms by which 
PKA pathway contributes to the initiation and/or development 
of adrenal disorders, it is essential to provide deeper insight of its 
interplay with other signaling pathways (Figure 3). Interestingly, 
WNT pathway activation has been involved in both PBMAH and 
PPNAD (70, 71) (Figure 2). Furthermore, as we will discuss in 
next sections, WNT pathway is also associated with ACA and 
ACC. A possible interplay between WNT/β-catenin and cAMP/
PKA pathways in the pathogenesis of adrenal hyperplasia and 
tumors would be an important point to further investigate with 
mouse models (Figure 3).
Cortisol-Producing Adenomas:  
PKA Pathway, PRKACA Mutations,  
and Lack of Mouse Models
As discussed above (Sections “Familial Forms of PBMAH, Genetic 
Alterations, and Related Mouse Models” and “Primary Pigmented 
Nodular Adrenocortical Disease and Related Mouse Models”), 
a number of genetic defects in the cAMP/PKA pathway have 
been associated with adrenal hyperplasia and related to cortisol 
hypersecretion (Figure 1). Somatic mutations of GNAS (72–74) 
and PRKAR1A (75) have also been found in CPAs (Figure  1). 
However, these mutations only accounted for a small subset of 
CPAs, which represent a relevant cause of CS. Recently, Beuschlein 
and collaborators identified a hotpsot mutation (L205R) in the 
PRKACA gene, encoding the catalytic subunit α (Cα) of PKA, in 
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Mouse model
Effects on adrenal
zonation and tumor
development
Adrenal Disease ?
?
Adrenal specific
Loss of function of R1α
CONSTITUTIVE PKA
CreAdrenal
R1a
AdKO
HYPERPLASIA
?Wnt
CONSTITUTIVE βCat
βCat
ADENOMA
CreAdrenal
∆Cat
Adrenal specific
Gain of function of βcatenin
?PKA
Gain of function of βcatenin
and
Loss of function of R1α
βCat
Proliferation
Oncogene
R1α
Survival
T. suppressor
ZF identity
PKA
Glucocorticoid
excess
ZG identity
Mineralocorticoid
excess
• ZF/ZG identity
• Survival/Proliferation
• Steroidogenesis
PKA signaling
patwway
βCat signaling
patwway
?
FiGURe 3 | interplay between the wNT/β-catenin and the cAMP/PKA pathways in the pathogenesis of adrenal hyperplasias and tumors. (A) Two 
mouse models recapitulating some of the most frequent alterations found in adrenal tumors in patients. AdKO mice developed cortical hyperplasia as a result of 
constitutive PKA activation due to gene inactivation of R1a regulatory subunit of PKA. The increased PKA signaling also favored zona fasciculata cell identity and 
glucocorticoid excess. ΔCat mice developed cortical adenoma as a result of constitutive b-catenin due to deletion of exon 3 in the gene encoding the b-catenin 
(Ctnnb1) leading to protein stabilization. Increased b-catenin activation also induced ectopic differentiation of zona glomerulosa and aldosterone excess. (B) Our 
models demonstrated that Prkar1a is a tumor suppressor and Ctnnb1 is an adrenal oncogene but secondary genetic alterations are required for malignant 
progression. A possible interplay between the WNT/β-catenin and the cAMP/PKA pathways in the adrenal cortex zonation and tumorigenesis is an important point 
to further investigate. The question can be genetically addressed by using compound transgenic mice based on previous available models and carrying both 
β-catenin and PKA constitutive activation.
7
Leccia et al. Mouse Models of Adrenocortical Tumors
Frontiers in Endocrinology | www.frontiersin.org July 2016 | Volume 7 | Article 93
more than one-third of patients with CPA (9). Four other groups 
subsequently reported the same mutation (72–74, 76). The 
PRKACA L205R mutation results in constitutive PKA activation 
(9, 74), which is a very likely cause of ACT formation (Figure 1). 
Supporting this hypothesis, patients with somatic mutations 
had adenomas, whereas patients with germline duplications had 
bilateral hyperplasias. Hence, PRKACA mutations, together with 
the previously identified GNAS and PRKAR1A inactivating muta-
tions, strongly support a crucial role of cAMP/PKA pathway in 
the tumorigenesis of CPAs. The development of knock-in mouse 
models bearing PRKACA activating L205R mutation is required 
to evaluate its driver potential and to provide new insights into 
the mechanisms underlying PKA-dependent tumorigenesis in 
the context of cortisol-producing ACAs. In addition, adding extra 
copies of Prkaca in mouse, by additive transgenesis or targeted 
transgenesis at the Rosa26 locus, would provide an opportunity 
to explore the pathogenic, maybe oncogenic, potential of PKA 
signaling. Such complementary mouse models would help 
understanding if gain-of-function mutations and gain of copy 
number alterations result in distinct adrenal lesions. Activating 
mutations in CTNNB1, the gene encoding β-catenin, have also 
been identified in CPAs (77). Interestingly, the recently identified 
PRKACA mutations were shown to be mutually exclusive with 
CTNNB1 mutations (72–74, 76). Therefore, a possible interplay 
between WNT/β-catenin and cAMP/PKA pathways in CPAs 
remains to be investigated. Once again, mouse models should be 
invaluable tools to address this question in vivo (Figure 3).
Aldosterone-Producing Adenomas:  
wNT Pathway, KCNJ5, and  
Lack of Mouse Models
In recent years, high throughput next-generation sequencing 
technologies have allowed major advances in the knowledge of 
the genetic bases of APAs. By comparing the APA exome to the 
germline exome, recurrent somatic mutations have been identi-
fied in genes coding for ion channels and transporters regulating 
the cell membrane potential. Specifically, mutated genes encoding 
ion channels include KCNJ5, which encodes the G-protein acti-
vated potassium channel GIRK4, and is mutated in about 26–40% 
of APAs (78, 79) and CACNA1D and CACNA1H genes encoding 
for voltage-dependent calcium channels (80, 81). Genes encoding 
regulators of the cell membrane potential include two ATPases, 
ATP1A1 and ATP2B3 (82). All these mutations ultimately lead 
to increased intracellular calcium and abnormal activation of 
calcium–calmodulin-dependent kinase (Ca2+–CAMK) signal-
ing, which plays a central role in aldosterone production. Before 
identification of these novel APA-associated genes, several mouse 
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models of potassium channels inactivation (KCNK3/KCNK9 
inactivation models) allowed understanding the effects of calcium 
homeostasis disruption and of some important aspects of PA 
(83–85). However, none of these models recapitulated hyperplasia 
and/or tumor development observed in human disease. Although 
one cannot exclude that mouse adrenal context may not be 
relevant to reproduce pathophysiological conditions associated 
with APA formation in humans, this suggests that in APAs, the 
tumorigenic potential could rely on a yet unidentified alteration. 
Among the newly identified genes, KCNJ5 mutations represent 
the most frequent genetic defects in APAs, with higher prevalence 
in the Japanese population (79). Thus, animal models of KCNJ5 
inactivation are warranted to confirm a central role for this gene 
in the initiation of APAs. However, Kcnj5 mRNA and KCNJ5 
protein are not expressed in the rat adrenal cortex, suggesting 
that it does not play a role in adrenal steroid production in this 
species and very likely in mice (86). Therefore, the demonstration 
that loss of KCNJ5 is sufficient to initiate both hyperaldosteron-
ism and tumor development will require genetic approaches in 
non-mouse systems, such as primary bovine adrenocortical cells 
and tissue reconstruction in xenografted mice.
Both cAMP/PKA and WNT/β-catenin pathways have been 
involved in the development of CPAs. Similarly, WNT/β-catenin 
pathway plays an important role in APA development, in addi-
tion to calcium signaling. Indeed, by generating a mouse model 
with constitutive β-catenin activation in the adrenal gland (ΔCat 
model), we found that these mice developed progressive dyspla-
sia and hyperplasia, ectopic differentiation of zona glomerulosa 
(ZG), and increased aldosterone production (Table  1). The 
ΔCat model will be further discussed in the ACC section. In a 
subsequent paper, Berthon and colleagues reported that WNT/β-
catenin pathway was aberrantly activated in 70% of a series of 
47 patients, which was the most frequent alteration reported in 
APAs (87). Furthermore, a recent study has reported CTNNB1 
mutations in 5.1% of a cohort of 198 APAs (88). These mutations 
were associated with stabilized β-catenin, suggesting activation 
of WNT pathway (Figure  2). Because of the higher frequency 
of WNT/β-catenin activation than of CTNNB1 mutations, it is 
essential to expand our knowledge of the other causes of aberrant 
WNT/β-catenin activation, by investigating other members of the 
pathway or possible crosstalks with other pathways. Interestingly, 
decreased expression of the WNT inhibitor SRFP2 was shown 
to contribute to deregulation of WNT/β-catenin pathway in the 
adrenal (87) (Figure 2).
ADReNOCORTiCAL CARCiNOMAS:  
THe LACK OF MOUSe MODeLS
Adrenocortical carcinomas are extremely rare, with an annual 
incidence of 0.5–2 cases per million in adults. However, they 
are highly aggressive tumors associated with poor prognosis 
and often diagnosed at an advanced stage for which available 
treatments are rarely curative. The overall 5-year survival rates 
range from 10 to 40% (6, 7). ACCs can occur at any age, but the 
incidence in children is particularly high in southern Brazil due 
to the high prevalence of a specific germline mutation (p.R337H) 
of the TP53 tumor suppressor gene (8). Pediatric and adult ACCs 
differ in genetics and many other ways (89, 90), as will be further 
discussed in Section “Pediatric ACCs: TP53, SF1, and Related 
Mouse Models.” Although most ACCs arise sporadically, an 
increased incidence of ACCs has been reported in some genetic 
syndromes, such as familial adenomatous polyposis (FAP), 
characterized by mutations in APC and elevated Wnt/β-catenin 
signaling, and Beckwith–Wiedemann syndrome (BWS), char-
acterized by elevated expression of insulin-like growth factor-2 
(IGF2) (91, 92).
The developmental context of the disease is crucial for the 
treatment and management of adrenal tumors. Therefore, there 
is a strong need to generate mouse models resembling human 
pathology, to identify the mechanisms involved in benign to 
malignant progression. Up to now, the three most frequent altera-
tions that have been reported in ACC patients include overex-
pression of IGF2 (93, 94), activation of WNT/β-catenin signaling 
pathway (11, 77, 95), and inactivation of TP53/RB pathway (96, 
97). Several mouse models of deregulation of these pathways have 
been generated, which allowed better understanding of adrenal 
tumorigenesis. However, none of these models was able to reca-
pitulate full-fledged ACC development (Table 1). In the following 
sections, we summarize mouse models of ACC generated up to 
now, and focus on what is still lacking for a better understanding 
of adrenal tumor initiation and progression.
Mouse Models of wNT/β-Catenin and 
iGF2 Signaling Activation Are insufficient 
to Trigger ACC Formation
The WNT/β-catenin pathway is essential for embryonic develop-
ment and cell renewal in adult adrenal cortex where β-catenin is 
expressed and active in ZG (98) (Figure 3). Several tumor profil-
ing studies have reported mutations in β-catenin gene (CTNNB1) 
in both ACAs and ACCs (77, 99, 100), suggesting that β-catenin 
activating mutations could be involved in adrenal tumor initia-
tion and progression to malignancy. To assess this hypothesis, we 
have generated a mouse model of constitutive β-catenin activa-
tion in the adrenal cortex (ΔCat mice) (25) (Figures  2 and 3; 
Table 1). ΔCat mice were generated by mating mice harboring a 
floxed allele of β-catenin [Catnblox(ex3)] (101) with mice expressing 
the Cre recombinase in steroidogenic cells of the adrenal cortex, 
through the Akr1b7 promoter region (67). Cre-mediated excision 
of the third exon of Ctnnb1 gene prevents β-catenin phospho-
rylation and ubiquitin-dependent degradation, which induces 
accumulation of the protein and constitutive activation of its 
target genes. ΔCat mice showed adrenal hyperplasia and ectopic 
differentiation of ZG. However, aggressive tumor formation was 
only observed in a subset of 17-month-old animals. Our model 
demonstrated that Ctnnb1 was an adrenal oncogene but it also 
suggested that secondary genetic alterations were required for 
malignant progression. Through a different approach, Hammer 
and colleagues obtained similar results by generating mice with 
adrenal cortex specific loss of Apc (APC KO mice) (26), a com-
ponent of the multi-protein destruction complex of β-catenin, 
to target WNT pathway activation (Figure  2). As ΔCat mice, 
APC KO mice displayed hyperplasia. Furthermore, hyperplasia 
progressed to microscopic and macroscopic adenomas as early as 
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15 weeks of age, but progression to carcinoma was never observed 
(Table 1). Results from our two groups suggest that constitutive 
activation of β-catenin initiates benign tumor development but is 
not sufficient to trigger malignant evolution.
Insulin-like growth factor-2 is a growth factor involved in 
the control of cell proliferation and inhibition of apoptosis and 
it was hypothesized to interact with the Wnt/β-catenin pathway. 
In sporadic adrenal tumors, IGF2 is overexpressed in 80–90% 
of ACCs but not in ACAs (93, 94). Several transgenic mouse 
models have been generated to explore the role of IGF2 in 
adrenal tumorigenesis (Table  1). Mice with overexpression of 
IGF2 under the control of phosphoenolpyruvate carboxykinase 
(PEPCK) promoter showed four- to sixfold elevation of serum 
IGF2 levels and mild adrenocortical hyperplasia but did not 
develop ACTs (27), suggesting that IGF2 overexpression was not 
involved in initiation of adrenal tumorigenesis. We have gener-
ated transgenic mice with adrenal cortex specific overexpression 
of IGF2 (AdIgf2 mice) (28) (Table  1). These mice had up to 
sevenfold higher basal levels of IGF2 (up to 87-fold higher with 
ACTH stimulation), but again they did not show tumor forma-
tion despite a mild increase in cortical cell proliferation. These 
results indicated that IGF2 alone could stimulate adrenal cortex 
proliferation but it was not able to induce oncogenic transforma-
tion. The mitogenic effect of IGF2 overexpression suggests a role 
in tumor maintenance rather than initiation, which would rather 
be triggered by other actors, such as WNT pathway. This two-
step model is supported by the fact that IGF2 overexpression is 
found only in ACCs, whereas mutations in β-catenin are reported 
in both ACAs and ACCs. To test the hypothesis of cooperation 
between IGF2 and WNT pathways, we generated a mouse model 
presenting both genetic alterations, by mating ΔCat mice with 
IGF2 overexpressing mice (28) (Table  1). Our analysis of this 
model clearly showed that IGF2 overexpression in the context 
of constitutive WNT/β-catenin pathway activation only had 
a moderate effect on tumor progression. In another approach, 
Hammer and collaborators generated a mouse model with both 
loss of APC, to achieve WNT activation, and loss of imprinting 
at the Igf2/H19 region, to achieve elevated IGF2 expression (26) 
(Table  1). These mice displayed adrenocortical hyperplasia, 
microscopic and macroscopic adenomas, and cancer formation. 
Although the phenotype was more severe than that observed in 
mice presenting loss of APC alone, only one cancer formation 
was observed. Taken together, these results have clearly shown 
that genetic alterations in WNT pathway and IGF2 overexpres-
sion are not sufficient to trigger malignant adrenocortical 
tumorigenesis. Interestingly, we recently reported that expression 
of enhancer of zeste 2 (EZH2), a histone methyl transferase of 
the polycomb repressive complex 2 (PRC2), positively correlated 
with malignancy and poor prognosis in three different cohorts 
of patients with ACTs (102). In this study, we provided evidence 
that in the H295R human adrenal cancer cell line, EZH2 down-
regulation or pharmacological inhibition significantly decreased 
cell proliferation and aggressive behavior and induced apoptosis. 
Interestingly, EZH2 overexpression was shown to be the result 
of P53/RB/E2F pathway deregulation in good agreement with 
ACC omic studies. Although this remains to be demonstrated 
in a relevant animal model, these data suggest that EZH2 could 
be involved in malignant progression. Mouse models with 
various ability to express Ezh2 (loss- and gain-of-function) are, 
thus, required to decipher the molecular mechanisms involved 
in EZH2-mediated malignant progression, i.e., transcription 
repression through PRC2 recruitment or activation (103) and 
to identify the actors that cooperate with WNT pathway in this 
process. Altogether, these mouse models indicate that malignant 
tumors may arise from typical adenomas even if this progression 
only affects a small proportion of benign tumors and requires 
additional alterations, such as EZH2 overexpression. One chal-
lenge of these studies is the evaluation of tumor staging in mouse 
models. Until now, mouse tumors have been evaluated with the 
same criteria as human tumors, i.e., essentially Weiss’s scoring. 
However, the transposability of these histologic criteria is unclear 
and the only undoubtful proof of malignant progression is meta-
static dissemination, which was not observed in any of the models 
discussed above. Irrespective of this issue, inheritable tumors in 
mouse genetic models provide an invaluable tool to follow tumor 
initiation and progression. Whole genomic analyses in such 
models would provide a unique opportunity to demonstrate or 
invalidate the existence of a normal adrenal adenoma–carcinoma 
continuum in adrenocortical tumorigenesis.
Pediatric ACCs: TP53, SF1,  
and Related Mouse Models
In addition to overexpression of IGF2 and activation of WNT 
pathway, the third most frequent genetic alteration in ACCs is 
inactivation of TP53/RB pathway. Germline mutations in the p53 
tumor suppressor gene are associated with the development of 
Li–Fraumeni syndrome (LFS), an autosomal-dominant cancer 
syndrome resulting in multiple malignancies, including ACCs 
(104, 105). The rate of germline TP53 mutations in ACCs is age-
dependent, ranging from up to 80% in pediatric ACCs (97) to 
3–7% in adults (96). A 10-fold increased incidence of ACCs is 
observed in Southern Brazil due to a germline mutation within 
the oligomerization domain of p53 (p.R337H). This germline 
mutation was first identified in 98% of children with ACCs (106). 
The p.R337H mutation was also present in 78% of children with 
sporadic ACTs in another series and in 13% of adult patients 
with ACCs (107). In adult ACTs, TP53 mutations are mostly 
somatic and were considered to represent a later step in tumo-
rigenesis (108, 109). Several mouse models of p53 dysfunction 
have been generated, including targeted mutations, replicating 
proteins identified in humans with LFS (110, 111). These mice 
developed a large spectrum of tumors but not ACCs. Mouse 
models of adrenal-specific TP53 loss have not been generated to 
date, despite the high prevalence of TP53 mutations in ACCs. 
However, the adrenocortical dysplasia (Acd) mouse model (112), 
carrying an inactivating mutation in Tpp/Acd, which normally 
functions to protect telomerase, was used to explore the conse-
quences of TP53 loss during adrenal tumorigenesis (Table  1). 
Interestingly, ablation of p53 (obtained by mating Acd mice with 
p53 null mice) rescued a number of characteristics of the Acd 
phenotype, including adrenal hypoplasia. This indicates that 
hypoplasia in Acd mice results from p53-mediated senescence. 
Moreover, the loss of p53 in Acd mice leads to development of 
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ACC, suggesting that p53-mediated escape from senescence 
may contribute to adrenocortical carcinogenesis (29). Another 
approach to explore the consequences of p53 ablation during 
adrenal tumorigenesis consists in adrenal targeting of the Simian 
Virus 40 (SV40) large T antigen (TAg), a potent oncogene acting 
in part by inactivating p53 [reviewed in (113)]. TAg expressed 
under the control of several promoters has been used to induce 
ACTs in transgenic mice. In the inhibin-α (inha) promoter-TAg 
mouse, ACCs are induced by gonadectomy (30) (Table 1). This 
mouse model will not be discussed in details here as mouse 
models of gonadectomy-induced ACTs are beyond the scope 
of this review, being unrelated to the context of human adrenal 
tumors. In order to better recapitulate the context of human 
adrenal tumor development, we have generated a model in 
which TAg is expressed under the control of the adrenal cortex 
specific Akr1b7 promoter (31) (Table 1). In this AdTAg model 2 
of 3 surviving founder mice developed adrenal tumors that were 
used to generate cell lines for further in vitro analysis (114). As 
exome sequencing and SNP array recently confirmed that p53/
RB is one of the most frequently altered pathways in ACCs (11), 
future mouse models are needed to further explore the role of 
TP53 in adrenal tumor formation and progression. Considering 
the well-characterized antagonism of large TAg toward p53 and 
Rb tumor suppressors, one would predict that the AdTAg model 
could provide one of the most relevant and simple models to 
explore adrenal tumorigenic processes.
Transcriptional profiling has demonstrated distinct signatures 
of adult and pediatric ACCs with the pediatric tumor transcrip-
tome displaying similarities to that of fetal adrenal tissue (115). 
Moreover, pediatric and adult ACCs differ in several clinical, 
pathological, and molecular aspects [reviewed in (90)], sug-
gesting that they may represent genetically distinct entities. In 
addition to TP53, the genetic locus containing steroidogenic 
factor 1 gene (SF-1) is commonly amplified and overexpressed 
in pediatric ACCs (116, 117). SF-1 is a nuclear receptor tran-
scription factor that plays an important role in the regulation of 
steroidogenic genes, in development and function of the adrenal 
cortex, and in male sexual differentiation (118, 119). In contrast 
to children, the frequency of amplification and overexpression 
in adult patients is very low (120), but it is associated with poor 
outcome (121). A transgenic mouse model, harboring multiple 
copies of a yeast artificial chromosome, including the SF-1 genetic 
locus, termed YACTR mice, has been generated (32) (Table 1). 
Although these mice developed adrenocortical hyperplasia 
that further progressed to adrenal tumors in a dose-dependent 
manner, the morphology of adrenal tumors differed from human 
ACTs and displayed a gonadal phenotype that was reminiscent 
of ACTs occurring in gonadectomized mice. These tumors are 
thought to arise from pluripotent adreno-gonadal precursor 
cells lying beneath the outer adrenal connective capsule, which 
have the potential to differentiate into cells of gonadal phenotype 
(122). Similarly, in YACTR mice, high levels of SF-1 may trigger 
proliferation of pluripotent cells and the development of adrenal 
tumors with a gonadal phenotype. Despite the differences in 
tumor phenotypes in human and mice, SF-1 appears to play an 
important role in adrenal tumorigenesis in both species. Recently, 
it has been proposed that SF-1 overexpression induces alterations 
of redox mechanisms, which may contribute to adrenal tumori-
genesis. Indeed, inactivation of SF1 target gene Vnn1, encoding 
the Vanin-1 protein involved in the response to oxidative stress, 
was found to antagonize the development of adrenocortical 
neoplasia in SF-1 transgenic mice (123).
Novel identified Genes in ACCs:  
interplays with wNT Pathway  
and Need for in vivo Studies
Recent OMIC studies confirmed that the most frequent genetic 
alterations in ACCs affect the tumor suppressor gene TP53 and 
the oncogene CTNNB1 (each being altered in ~16% of ACCs) 
(11, 124). In addition to pointing out alterations in already 
known drivers (CTNNB1 and TP53), these studies identified 
new genes not previously reported in ACCs. Among these new 
genes, ZNRF3 was found to be the most frequently altered (21% 
of ACCs). ZNRF3 encodes a protein with E3 ubiquitin ligase 
activity, supposed to act as a negative regulator of the WNT/β-
catenin pathway (125) (Figure  2). ACCs with alterations in 
ZNRF3 locus showed activation of β-catenin target genes, but 
this activation was weaker than in tumors with CTNNB1 muta-
tions (11). Interestingly, ZNRF3 and CTNNB1 alterations were 
mutually exclusive. Further functional studies and novel mouse 
models are needed to further explore the role of ZNRF3 in ACCs. 
Recurrent mutations have also been found in several known cell 
cycle regulators, including CDKN2A, CDK4, RB1, and CCNE1, 
confirming the notion that release from p53-sensitive check-
points is a critical step in the process of adrenal tumorigenesis, 
a notion that previously emerged from analysis of p53 ablation 
in Acd mice.
Recently, mutations have also been found in PRKAR1A (126), 
a gene mutated in PPNAD (as discussed in Section “Primary 
Pigmented Nodular Adrenocortical Disease and Related Mouse 
Models”) and much more rarely in ACAs (as discussed in Section 
“Cortisol-Producing Adenomas: PKA Pathway, PRKACA 
Mutations, and Lack of Mouse Models”). These recent reports of 
PRKAR1A mutations expand the role of PKA signaling in ACC. 
If any functional interplay exists between the WNT/β-catenin 
and the cAMP/PKA pathways in the pathophysiology of adrenal 
cortex, this is an important point that remains to be clarified 
in  vivo (Figure  3). As reviewed in Drelon’s study (127) data 
from the literature are in favor of such an interplay. This could 
influence normal adrenal cortex renewal/zonation as well as the 
pathophysiology of human adrenal tumors. However, whether 
these pathways cooperate or antagonize each other remains to 
be determined. This question could be genetically addressed by 
generating compound transgenic mice based on already avail-
able models carrying β-catenin and PKA constitutive activation 
(Figure 3) (23, 25).
FUTURe DiReCTiONS
The understanding of mechanisms of adrenal tumor progression is 
crucial for the management and treatment of the disease. Indeed, 
almost half of ACC patients present with metastatic disease and 
although mitotane alone or in combination with chemotherapy 
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can improve patients’ survival, there is no efficient treatment for 
advanced disease. There is, thus, a strong need to generate mouse 
models resembling human pathology to identify actors involved 
in adrenal carcinogenesis. Especially, mouse models testing the 
role of newly identified genes in pediatric and adult ACCs are 
warranted. Moreover, as recent OMIC approaches confirmed that 
p53/RB is one of the most frequently altered pathways in ACCs 
(11), the AdTAg mouse model, previously used to generate cell 
lines for in vitro analyses (114), now becomes a relevant model 
for the study of ACCs.
The study of molecular mechanisms underlying malignant 
tumor progression represents a crucial step to develop novel 
specific drugs. The next step is to test their efficacy through 
in  vitro and in  vivo experiments. The only available “in  vivo” 
model is the ACC xenograft obtained by subcutaneous injection 
of the H295R cell line in nude mice (128). Although this model 
has been extensively used to evaluate new and established drugs, 
it is important to take its limitations into account. These include 
deregulated antitumoral response resulting from immunodefi-
ciency and abnormal or deficient microenvironment associated 
with subcutaneous injection of cells. Therefore, the AdTAg mouse 
model could be a useful experimental platform to assess in vivo 
the role of newly identified candidates potentially involved in 
malignant progression, such as EZH2 (102), using genetic or 
pharmacological approaches. Considering pediatric adrenal 
cancers, knock-in mouse models reproducing TP53 p.R337H 
mutation found in Brazilian families will be a major advance 
in our understanding of the pathogenesis of these destructive 
tumors. There is, thus, a strong need for novel mouse models for 
preclinical studies.
Finally, high throughput next-generation sequencing tech-
nologies have allowed major advances in the knowledge of 
the genetic bases of ACAs. Among the newly identified genes, 
ARMC5, KCNJ5, and PRKACA mutations represent the most 
frequent genetic defects in PBMAH, APAs, and CPAs, respec-
tively (10, 39, 61, 62, 72–74, 79). Mouse models are required 
to confirm the driving potential of these genes in the initiation 
and/or progression of ACAs. In conclusion, we expect that the 
progress in gene editing methods and the recent identification of 
new recurrently mutated genes, will soon allow the development 
of novel mouse models capable of faithfully reproducing human 
adrenal diseases, overcoming the limitations of current models. 
These models will be useful, on the one hand, to investigate 
the mechanisms underlying malignant progression of adrenal 
tumors and, on the other hand, to develop novel therapeutic 
approaches.
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